[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Moderna Inc (MRNA)

Moderna Inc (MRNA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

MRNA Stock Alert: Moderna Surges on Hantavirus Vaccine Hopes

Moderna (MRNA) stock pushed meaningfully higher on Friday following reports that the biotech giant is leveraging its mRNA platform to develop a vaccine for hantavirus. 

The news, which arrived after a deadly Hantavirus outbreak on the MV Hondius cruise ship, helped MRNA break above key resistance levels coinciding with its 20-day and 50-day MA. 

Fundamentals

See More
  • Market Capitalization, $K 21,565,320
  • Shares Outstanding, K 396,786
  • Annual Sales, $ 1,944 M
  • Annual Income, $ -2,822 M
  • EBIT $ -3,412 M
  • EBITDA $ -3,264 M
  • 60-Month Beta 1.05
  • Price/Sales 9.91
  • Price/Cash Flow N/A
  • Price/Book 2.60

Options Overview Details

View History
  • Implied Volatility 91.11% (+17.70%)
  • Historical Volatility 58.74%
  • IV Percentile 99%
  • IV Rank 75.20%
  • IV High 103.33% on 11/03/25
  • IV Low 54.03% on 08/06/25
  • Expected Move (DTE 5) 5.13 (9.45%)
  • Put/Call Vol Ratio 0.13
  • Today's Volume 205,259
  • Volume Avg (30-Day) 56,017
  • Put/Call OI Ratio 0.80
  • Today's Open Interest 716,430
  • Open Int (30-Day) 706,900
  • Expected Range 49.22 to 59.48

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 23 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-2.09
  • Number of Estimates 10
  • High Estimate $-1.83
  • Low Estimate $-2.35
  • Prior Year $-2.13
  • Growth Rate Est. (year over year) +1.88%

Price Performance

See More
Period Period Low Period High Performance
1-Month
43.68 +24.43%
on 05/01/26
57.78 -5.93%
on 05/08/26
+2.25 (+4.32%)
since 04/08/26
3-Month
36.65 +48.27%
on 02/11/26
59.55 -8.73%
on 03/04/26
+13.34 (+32.53%)
since 02/06/26
52-Week
22.28 +143.94%
on 11/21/25
59.55 -8.73%
on 03/04/26
+29.97 (+122.93%)
since 05/08/25

Most Recent Stories

More News
MRNA Stock Alert: Moderna Surges on Hantavirus Vaccine Hopes

Moderna shares rally as investors bet on recent Hantavirus outbreak accelerating the biotech firm’s path to profitability. But there are ample reasons to avoid buying MRNA stock today.

MRNA : 54.35 (+11.97%)
Moderna (MRNA) Shares Skyrocket, What You Need To Know

Moderna (MRNA) Shares Skyrocket, What You Need To Know

MRNA : 54.35 (+11.97%)
5 Insightful Analyst Questions From Moderna’s Q1 Earnings Call

5 Insightful Analyst Questions From Moderna’s Q1 Earnings Call

MRNA : 54.35 (+11.97%)
FDA's new playbook: Lots of media announcements but not much rulemaking

Health Secretary Robert F. Kennedy Jr. and other health officials have repeatedly announced major changes before any new rules have been drafted

MRNA : 54.35 (+11.97%)
Is Wall Street Bullish or Bearish on Moderna Stock?

Moderna has notably outperformed the broader market over the past year, yet Wall Street analysts maintain a cautious outlook about the stock’s prospects.

$SPX : 7,398.93 (+0.84%)
IBB : 169.94 (-0.09%)
MRNA : 54.35 (+11.97%)
Moderna Announces New England Journal of Medicine Publication of Pivotal Phase 3 Clinical Safety and Efficacy Data for Its Investigational Seasonal Influenza Vaccine, mRNA-1010

Regulatory filings are under review in the U.S., Europe, Canada and Australia, with potential approvals expected to begin in 2026

MRNA : 54.35 (+11.97%)
Option Volatility And Earnings Report For May 4 - 8

We have Palantir, Advanced Micro Devices, Coinbase, Coreweave, Arista Networks, Arm Holdings, Shopify and Uber Technologies all reporting in what shapes as a busy and pivotal week for stocks.

MSTR : 187.59 (+4.31%)
GOOG : 397.05 (+0.44%)
ANET : 141.77 (+0.01%)
COIN : 201.16 (+4.25%)
SHOP : 110.41 (-1.19%)
CRWV : 114.15 (-11.40%)
TSLA : 428.35 (+4.02%)
AMD : 455.19 (+11.44%)
RKT : 15.69 (+10.88%)
PINS : 21.27 (-1.30%)
ARM : 213.27 (-0.02%)
MRNA : 54.35 (+11.97%)
MRNA Q1 Deep Dive: International Partnerships and Pipeline Progress Offset Litigation Headwinds

MRNA Q1 Deep Dive: International Partnerships and Pipeline Progress Offset Litigation Headwinds

MRNA : 54.35 (+11.97%)
Moderna (NASDAQ:MRNA) Beats Expectations in Strong Q1 CY2026, Stock Soars

Moderna (NASDAQ:MRNA) Beats Expectations in Strong Q1 CY2026, Stock Soars

MRNA : 54.35 (+11.97%)
Moderna: Q1 Earnings Snapshot

Moderna: Q1 Earnings Snapshot

MRNA : 54.35 (+11.97%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 50%. The market is indicating support for a bullish trend.

See More Share

Business Summary

Moderna, Inc. is a clinical-stage pharmaceutical company, primarily focused on discovering and developing messenger RNA (mRNA) based therapies. The company's mRNA based COVID-19 vaccine, Spikevax (mRNA-1273), is approved for use in adults in the United States. The vaccine is also authorized for emergency...

See More

Key Turning Points

3rd Resistance Point 67.22
2nd Resistance Point 62.50
1st Resistance Point 58.43
Last Price 54.35
1st Support Level 49.63
2nd Support Level 44.90
3rd Support Level 40.83

See More

52-Week High 59.55
Last Price 54.35
Fibonacci 61.8% 45.31
Fibonacci 50% 40.92
Fibonacci 38.2% 36.52
52-Week Low 22.28

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.